In the current study, the researchers first examined the effects of knocking out Ngly1 in mice. They found that when mice lacked both Ngly1 genes--one from each parent--they always died just before birth. However, a double knockout of both Ngly1 and ENGase genes resulted in mice that survived after birth, but not for very long.
This positive result was actually unexpected. "We thought that ENGase acted further downstream to Ngly1 in the catabolism of glycoproteins" notes team leader Dr. Tadashi Suzuki, "and were surprised when the double knockout was able to suppress the lethality of Ngly1-KO mice. If ENGase was merely an enzyme downstream of Ngly1, nothing should have happened. This was truly a case of serendipity."
Although the double-knockout mice survived, they shared several defects that are similar to the symptoms observed in people with NGLY1-deficiency. As these mice aged, they developed characteristics such as bent spines, trembling, limb-clasping and shaking, and by 45 weeks, the survival rate was reduced to 60%. These mice could therefore be useful model mice for developing treatments for the human genetic disorder.
Another factor affecting survival and symptoms turned out the be the genetic background of the mice, that is, the genotypes of all genes related to Ngly1 and Engase, which likely affect how they function. When mice were crossed with an outbred strain, the single Ngly1 knockout proved less lethal, and the double knockout proved to be even more helpful, with mice only showing hind-limb clasping after 30 weeks.
These findings show that the biological processes involved are quite complicated. Despite this however, it is clear that preventing ENGase from acting can alleviate symptoms of Ngly1 deficiency in mice. Figuring out which aspects of the genetic background help reduce symptoms is perhaps a long-term goal.
Although the condition was only recently discovered, research into NGLY1-deficiency has been facilitated through efforts from the Grace Science Foundation, and the RIKEN team has recently begun a collaboration with Takeda Pharmaceuticals and T-CiRA at Kyoto University.
"For now, the next step," says Dr. Suzuki, "will be to isolate an in vivo inhibitor for ENGase and determine whether it can improve the symptoms related to NGLY1-deficiency. As we do not know much about the pathophysiology of the disorder, this might help us find potential targets for therapy, but also might lead to a better understanding of other diseases. Such chains of unexpected results are the beauty of basic science!"